Investment Thesis
Immix Biopharma is a clinical-stage pharmaceutical company with severe fundamental deterioration: operating losses of $30M against only $20M revenue, negative operating cash flow of $23.9M, and a burn rate of ~120% of revenue. While the strong balance sheet ($93.9M cash, minimal debt) provides 3-4 year runway, the fundamental inability to generate positive cash flow or profitability presents substantial downside risk without successful drug development.
Strengths
- Fortress balance sheet with $93.9M cash versus $11.0M total liabilities (net cash position)
- Exceptional liquidity: 10x current and quick ratios provide operational runway
- Pharmaceutical sector with potential for significant value creation from successful drug candidates
Risks
- Extreme operating losses: -$30M operating income on $20M revenue (-149.8% operating margin)
- Negative operating cash flow of -$23.9M indicating unsustainable business model burn rate
- Estimated 3.9 year cash runway at current burn rates before depletion without profitability
- No visibility into drug pipeline success probability, clinical trial timelines, or regulatory pathway
- Zero insider Form 4 filings in 90 days suggesting limited management confidence or activity
Key Metrics to Watch
- Operating cash flow trajectory and monthly burn rate reduction
- Revenue growth acceleration and commercial product launch timeline
- Clinical trial advancement, FDA milestone achievement, and regulatory approvals
- Cash balance depletion rate and requirement for additional financing
Financial Metrics
Revenue
20.0M
Net Income
-29.4M
EPS (Diluted)
$-0.89
Free Cash Flow
-24.7M
Total Assets
104.8M
Cash
93.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-149.8%
Net Margin
-147.2%
ROE
-31.4%
ROA
-28.1%
FCF Margin
-123.3%
Balance Sheet & Liquidity
Current Ratio
10.01x
Quick Ratio
10.01x
Debt/Equity
0.00x
Debt/Assets
10.5%
Interest Coverage
-60,274.48x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-11T18:36:28.409639 |
Data as of: 2025-12-31 |
Powered by Claude AI